Modality
ADC
MOA
SOS1i
Target
IL-13
Pathway
PD-1/PD-L1
NMOSDPsA
Development Pipeline
Preclinical
~Dec 2020
→ ~Mar 2022
Phase 1
Jun 2022
→ Nov 2025
Phase 1Current
NCT03595849
281 pts·NMOSD
2022-06→2025-11·Terminated
281 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-11-035mo agoPh2 Data· NMOSD
Trial Timeline
Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q4
P1/2
Termina…
Catalysts
Ph2 Data
2025-11-03 · 5mo ago
NMOSD
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03595849 | Phase 1/2 | NMOSD | Terminated | 281 | ORR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2901 | Pfizer | Phase 2 | AHR | |
| Lisonaritide | Eli Lilly | Phase 3 | IL-13 | |
| MRK-1380 | Merck & Co | Preclinical | SHP2 | |
| Sovarapivir | AbbVie | Phase 2/3 | IL-13 | |
| Terarelsin | AbbVie | Preclinical | SOS1 | |
| Doxarapivir | Bristol-Myers Squibb | Phase 3 | KRASG12C | |
| Ceviderotide | Novo Nordisk | Preclinical | IL-13 | |
| DSN-3066 | Daiichi Sankyo | Phase 3 | IL-13 | |
| DSN-6862 | Daiichi Sankyo | Preclinical | IL-23 | |
| GIL-2011 | Gilead Sciences | Preclinical | VEGF |